Guizhou Xinbang Pharmaceutical Co., Ltd. (SHE:002390)
China · Delayed Price · Currency is CNY 3.300
+0.120 (3.77%)
Apr 29, 2026, 3:04 PM CST
SHE:002390 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 5,620 | 6,000 | 6,436 | 6,331 | 6,441 |
Other Revenue | - | 32.17 | 24.98 | 19.36 | 30.76 |
| 5,620 | 6,032 | 6,461 | 6,350 | 6,472 | |
Revenue Growth (YoY) | -6.84% | -6.63% | 1.75% | -1.88% | 10.71% |
Cost of Revenue | 4,628 | 5,000 | 5,240 | 5,133 | 5,119 |
Gross Profit | 991.73 | 1,032 | 1,221 | 1,217 | 1,352 |
Selling, General & Admin | 609.66 | 669.9 | 737.84 | 814.14 | 766.62 |
Research & Development | 5.8 | 4.59 | 4.67 | 1.21 | 1.94 |
Other Operating Expenses | 33.35 | 25.01 | 22.57 | 28.19 | 28.7 |
Operating Expenses | 648.81 | 749.07 | 830.01 | 884.14 | 823.94 |
Operating Income | 342.92 | 282.84 | 391.05 | 332.82 | 528.56 |
Interest Expense | - | -23.54 | -39.7 | -51.79 | -100.19 |
Interest & Investment Income | 19.74 | 10.76 | 22.13 | 50.97 | 17.92 |
Currency Exchange Gain (Loss) | - | -0 | 0 | 0 | -0 |
Other Non Operating Income (Expenses) | -110.53 | -18.96 | 11.01 | -22.76 | -4.47 |
EBT Excluding Unusual Items | 252.12 | 251.1 | 384.49 | 309.25 | 441.82 |
Gain (Loss) on Sale of Assets | -0.48 | -2.29 | 0.02 | -0 | -0.42 |
Asset Writedown | -21.67 | -1.11 | -0.56 | -2.13 | -4.04 |
Other Unusual Items | - | -62.2 | 12.08 | 6.28 | -16.23 |
Pretax Income | 229.96 | 185.5 | 396.02 | 313.39 | 421.12 |
Income Tax Expense | 38.17 | 29.81 | 42.25 | 45.14 | 47.17 |
Earnings From Continuing Operations | 191.8 | 155.69 | 353.77 | 268.26 | 373.96 |
Minority Interest in Earnings | -71.51 | -54.31 | -66.54 | -43.88 | -101.09 |
Net Income | 120.29 | 101.38 | 287.23 | 224.37 | 272.87 |
Net Income to Common | 120.29 | 101.38 | 287.23 | 224.37 | 272.87 |
Net Income Growth | 18.65% | -64.70% | 28.02% | -17.77% | 57.25% |
Shares Outstanding (Basic) | 1,897 | 2,028 | 1,915 | 1,870 | 1,819 |
Shares Outstanding (Diluted) | 1,897 | 2,028 | 1,915 | 1,870 | 1,819 |
Shares Change (YoY) | -6.43% | 5.89% | 2.41% | 2.79% | 15.32% |
EPS (Basic) | 0.06 | 0.05 | 0.15 | 0.12 | 0.15 |
EPS (Diluted) | 0.06 | 0.05 | 0.15 | 0.12 | 0.15 |
EPS Growth | 26.80% | -66.67% | 25.00% | -20.00% | 36.36% |
Free Cash Flow | 647.11 | 510.1 | 654.84 | 432.02 | 204.21 |
Free Cash Flow Per Share | 0.34 | 0.25 | 0.34 | 0.23 | 0.11 |
Dividend Per Share | - | 0.060 | 0.060 | 0.060 | 0.060 |
Gross Margin | 17.65% | 17.11% | 18.90% | 19.16% | 20.90% |
Operating Margin | 6.10% | 4.69% | 6.05% | 5.24% | 8.17% |
Profit Margin | 2.14% | 1.68% | 4.45% | 3.53% | 4.22% |
Free Cash Flow Margin | 11.52% | 8.46% | 10.13% | 6.80% | 3.16% |
EBITDA | 540.18 | 491.06 | 619.72 | 567.89 | 767.42 |
EBITDA Margin | 9.61% | 8.14% | 9.59% | 8.94% | 11.86% |
D&A For EBITDA | 197.27 | 208.22 | 228.67 | 235.06 | 238.86 |
EBIT | 342.92 | 282.84 | 391.05 | 332.82 | 528.56 |
EBIT Margin | 6.10% | 4.69% | 6.05% | 5.24% | 8.17% |
Effective Tax Rate | 16.60% | 16.07% | 10.67% | 14.40% | 11.20% |
Revenue as Reported | - | 6,032 | 6,461 | 6,350 | 6,472 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.